Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004302
Abstract: Backgrounds Proficient-mismatch-repair or microsatellite stability (pMMR/MSS) colorectal cancer (CRC) has limited efficacy for immune checkpoint blockade (ICB) therapy and its underlying mechanism remains unclear. Guanylate binding protein 2 (GBP2) is a member of the GTPase… read more here.
Keywords: gbp2; mss crc; cancer; crc ... See more keywords
Preliminary efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR/MSS locally advanced rectal cancer (ESTIMATE): A prospective, single-arm, phase II trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e15602
Abstract: e15602 Background: Patients with locally advanced rectal cancer (LARC) experience benefits from total neoadjuvant therapy (TNT). This study aims to explore the efficacy and safety of combining TNT with immunotherapy for pMMR/MSS LARC patients. Methods:… read more here.
Keywords: locally advanced; pmmr mss; rectal cancer;
IDOV-Safe: An intravenously deliverable oncolytic vaccinia virus for solid tumors refractory to standard of care—preliminary results from the pMMR/MSS CRC cohort.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e15556
Abstract: e15556 Background: Metastatic pMMR/MSS colorectal cancer (CRC) remains challenging to treat following progression on oxaliplatin- and irinotecan- based therapies, with limited responsiveness to PD-1/PD-L1 inhibitors. Oncolytic viruses (OVs) offer a promising new approach to bio-immunotherapy… read more here.
Keywords: idov; pmmr mss; idov safe; phase ... See more keywords
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2024 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s500281
Abstract: Abstract Immunotherapy is one of the research hotspots in colorectal cancer field in recent years. The colorectal cancer patients with mismatch repair-deficient (dMMR) or high microsatellite instability (MSI-H) are the primary beneficiaries of immunotherapy. However,… read more here.
Keywords: colorectal cancer; immunotherapy; cancer; pmmr mss ... See more keywords
Gamma Knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis
Sign Up to like & getrecommendations! Published in 2024 at "eLife"
DOI: 10.7554/elife.103559
Abstract: An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges. In this phase II trial, patients received Gamma Knife SBRT combined with Tislelizumab. P Biomarker… read more here.
Keywords: pmmr mss; phase trial; knife; combined tislelizumab ... See more keywords